The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

Exclusion Criteria

• •1. Severe hypertension patients; more 110mmHg of SiDBP and/or more 180 mmHg of Sitting systolic blood pressure (SiSBP)
• •2. Patients with secondary hypertension
• •3. Patients with significant investigations - abnormal renal function (Creatinine more than upper limit of normal), abnormal liver function (AST, ALT more 2 times than upper normal), moderate fatty lever needed medication
• •4. Patients with hypotension who has sign and symptom
• •5. Patients with surgical and medical disease it is able to be affect to absorption, distribution, metabolism, excretion
• •6. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c \> 9%, regimen change of oral hypoglycemic agent, using insulin)
• •7. Patients with severe heart disease, ischemic heart disease within 6months, peripheral vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary Artery Bypass Graft (CABG)
• •8. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia
• •9. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve disease
• •10. Patients with severe cerebrovascular disease
• •11. Patients with wasting disease, autoimmune disease, connective tissue disease at present and/or previous.
• •12. Patients with known severe or malignancy retinopathy
• •13. Patients with hepatitis B or C or HIV positive reaction
• •14. Patients who have a story or evidence of alcohol or drug abuse within 2years
• •15. Patients who are measured the mean difference of mean blood pressure of both arm under SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit
• •16. Patients with history of allergic reaction to any angiotensin II antagonist
• •17. Patients with any chronic inflammation disease needed to chronic inflammation therapy
• •18. Childbearing and breast-feeding women
• •19. Female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods
• •20. Patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial
• •21. Subject who are judged unsuitable to participate in this study by investigator